We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
Cap. Flow
-$140M
Cap. Flow %
-9.32%
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
2
OGN icon
Organon & Co
OGN
+$23M
3
CYH icon
Community Health Systems
CYH
+$19.2M
4
RCM
R1 RCM Inc. Common Stock
RCM
+$18.6M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$71.3M
2
GSK icon
GSK
GSK
+$28.4M
3
TGTX icon
TG Therapeutics
TGTX
+$27.2M
4
ELV icon
Elevance Health
ELV
+$20.5M
5
CTLT
CATALENT, INC.
CTLT
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.27%
2 Miscellaneous 33.54%
3 Industrials 1.14%
4 Financials 0.05%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
101
MannKind Corp
MNKD
$1.27B
– –
-2,165,383
Closed -$8.49M
NVAX icon
102
Novavax
NVAX
$1.53B
– –
-33,473
Closed -$6.13M
PRTA icon
103
Prothena Corp
PRTA
$479M
– –
-68,575
Closed -$1.72M
QDEL icon
104
QuidelOrtho
QDEL
$1.01B
– –
-4,132
Closed -$529K
SRDX
105
DELISTED
Surmodics
SRDX
– –
-47,906
Closed -$2.69M
XGN icon
106
Exagen
XGN
$179M
– –
-104,437
Closed -$1.83M
CTLT
107
DELISTED
CATALENT, INC.
CTLT
– –
-163,114
Closed -$17.2M
DCPH
108
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-345,717
Closed -$15.5M
RAD
109
DELISTED
Rite Aid Corporation
RAD
– –
-54,025
Closed -$1.11M
APTO
110
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-178
Closed -$478K
OTIC
111
CALL
DELISTED
Otonomy, Inc.
OTIC
– –
-198,400
Closed -$506M
CFMS
112
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-61,679
Closed -$1.53M
ALXN
113
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-465,983
Closed -$71.3M
LMNX
114
DELISTED
Luminex Corp
LMNX
– –
-135,471
Closed -$4.33M
FPRX
115
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-93,280
Closed -$3.51M
BHVN
116
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-242,172
Closed -$16.6M
1 2 3 4
5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.

  • Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
  • Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
  • Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
  • Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
  • Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.